
THE ANALYSIS OF MICRONUCLEI FREQUENCY IN
A CONTROL SAMPLE, AND IN HORMONALLY-
TREATED FEMALE PATIENTS ATTENDING THE
KRAGUJEVAC HOSPITAL, SERBIA, YUGOSLAVIA
Milosevic-Djordjevic O1, Grujicic D1, Marinkovic D2, Arsenijevic S3,
Joksic G4, Jankovic S5
*Corresponding Author: Dr. Olivera Milosevic-Djordjevic, Faculty of Sciences, University of Kragujevac, Institute of Biology, Department of Genetics, Radoja Domanovica 12, P.O. Box 60, 34000 Kragujevac, Serbia, Yugoslavia; Tel: +381-34-336-223 to 330; Fax: +381-34-335-040; E-mail: darko@knez.uis.kg.ac.yu page: 37
|
INTRODUCTION
Micronuclei (MN) in cells undergoing mitosis arise from structural chromosomal aberrations or disturbed function of the mitotic spindle. Some authors consider that MN frequencies in peripheral blood lymphocytes of human individuals provide an effective estimate of the effects of physical and chemical factors [1]. This test permits an analysis of a great number of lymphoblasts per sample, which is important for a more realistic picture of the cell’s cytogenetic damage, as well as for the discovery of genotoxic effects in tested preparations [2-4]. In previous papers [5,6], we have shown that gestagens (progesterone and its derivatives) induce a significant increase of MN frequency in female patients who maintained their pregnancies by taking these preparations, as well as in their newborns.
Progesterone and its derivatives are a significant group of medicines with an important application in the prevention of spontaneous abortions. A considerable quantity of progesterone changes the ultrastructure of uterus muscles, and in this way inhibits spontaneous contractions and the possibility of abortion [7]. Since they are frequently used, and their activity is realized by direct influence on DNA molecules [8], the need arises to test these preparations for genotoxicity. The aim of this study was the determination of average MN frequency in dependence on gestagen type, as well as to show variability of frequencies of this phenotypical characteristic by the application of analysis of variance (ANOVA).
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|